COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
12/02/2026
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has [...]
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
12/02/2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its [...]
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi
12/02/2026
Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul [...]
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
12/02/2026
Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% 1 en Oncologie, 102,5% [...]
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
12/02/2026
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul [...]
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
12/02/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the [...]
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
12/02/2026
FY 2025 sales growth of 10.9% at CER 1 , or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% 1 ), Rare Disease (102.5% 1 ) and Neuroscience (9.7% 1 ); Somatuline® sales growth of 4.3% [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Nicox confirme son éligibilité au PEA-PME
12/02/2026
Communiqué de presse Nicox confirme son éligibilité au PEA-PME 12 février 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
12/02/2026
Oslo, Norway, 12 th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin [...]
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
12/02/2026
Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results [...]
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
12/02/2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness. 2026 guidance reflects continued growth in Travel Health (10% from own [...]
BioRestorative Announces Pricing of $5.0 Million Public Offering
12/02/2026
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell- [...]
Xilio Therapeutics Announces Pricing of Underwritten Offering
12/02/2026
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
11/02/2026
Launch of Inspire V system complete with strong revenue and profitability performance in the fourth quarter and FDA approval for 3.0T MRI compatibility Fourth quarter revenue growth of 12% and full year revenue growth [...]
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
11/02/2026
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review [...]
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
11/02/2026
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
11/02/2026
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth [...]
Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
11/02/2026
Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that [...]

Pages